Rhythm Pharmaceuticals, Inc. RYTM Interest Expense
Interest Expense at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s interest expense?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported interest expense of $4.58M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s interest expense decreased by 15.3% year-over-year, from $5.41M to $4.58M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s interest expense?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s interest expense has grown at a 58.2% compound annual growth rate (CAGR), from $5.2M to $20.58M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.